Cargando…

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies

BACKGROUND: Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activity against nontuberculous mycobacteria, is under clinical development for treatment of MAC lung disease. A population pharmacokinetic (PK) model describing the disposition of EBO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ganesan, Harish, Courtney Safir, M, Bhavnani, Sujata M, Krause, Kevin M, Rubino, Christopher M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752197/ http://dx.doi.org/10.1093/ofid/ofac492.645

Ejemplares similares

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods
por: Zhang, Li, et al.
Publicado: (2019)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

1727. Phase 1b Dose-ranging Study Demonstrates Tolerability and Pharmacokinetics (PK) of Oral Epetraborole at the Predicted Therapeutic Dosage for Mycobacterium avium Complex (MAC) Lung Disease
por: Eckburg, Paul B, et al.
Publicado: (2022)

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive
por: Safir, M. Courtney, et al.
Publicado: (2020)

The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex
por: O’Donnell, John P, et al.
Publicado: (2023)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development
por: Bhavnani, Sujata M, et al.
Publicado: (2020)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
por: Onufrak, Nikolas J, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
por: Ganesan, H., et al.
Publicado: (2023)

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies
por: Trang, Michael, et al.
Publicado: (2019)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment-Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease
por: Rubino, Christopher M., et al.
Publicado: (2021)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

2135. Epetraborole in vitro Activity Against Mycobacterium avium complex Recent Clinical Isolates from Japan
por: White, Tiffany Keepers, et al.
Publicado: (2023)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

228. Epidemiology and Susceptibility Profiles of ST131-O25b Escherichia coli Detected Among Cephalosporin and/or Carbapenem-Resistant Isolates Collected in United States Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Epetraborole Is Active against Mycobacterium abscessus
por: Ganapathy, Uday S., et al.
Publicado: (2021)

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
por: Lepak, Alexander, et al.
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Impact of antibiotic pharmacokinetics in urine on recurrent bacteriuria following treatment of complicated urinary tract infections
por: Melnick, David, et al.
Publicado: (2023)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mfo53n4pctsqbhpj34doummu94